# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN-TD
- Date: 1705-02-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Delacroix-Boateng, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He fears another attack of fever at sea, where he would be far from a laboratory and responsible for the squadron **S**
- He must have every vaccine and certificate that entry to French Guiana and the islands requires before the squadron sails **S**

## Your goals

- No further malaria relapse in the six months after radical cure. Target: 1705-10-13. Recorded outcome: No fever in the seven months since finishing primaquine. **S**
- All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure. Target: 1705-10-13. Recorded outcome: Yellow fever, hepatitis A dose 1, hepatitis B two-dose series, typhoid and influenza vaccines given; certificate valid. **S**
- Knows to have a malaria test the same day for any fever, during travel and for months after return. Target: 1705-03-31. Recorded outcome: Carries a fever card and explained the plan back correctly. **S**

## What we agreed to do

- Infectious diseases (travel medicine) consultation in two weeks to establish the cause of the recurrent fevers, advise on antirelapse treatment, and plan pre-travel care for the deployment. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006) **S**
- Malaria testing between attacks: thick and thin blood smears, rapid antigen test, and Plasmodium species PCR sent to the reference laboratory; quantitative G6PD activity before any primaquine; blood count, kidney and liver tests. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026) **S**
- Fever action plan: a blood smear the same day for any fever, at home, at sea or after travel; carry a card stating his malaria history. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026) **S**
- Chloroquine for the blood stage (1,000 mg salt, then 500 mg at 6, 24 and 48 hours) and primaquine 30 mg base daily for 14 days for radical cure, with the normal G6PD result; blood count and bilirubin after the course; report dark urine, breathlessness or blue lips. Guideline: Treatment of Uncomplicated Malaria (clinical guidance) (2026) **S**
- Pre-travel plan for French Guiana and the Antilles: one dose of yellow fever vaccine with the certificate, hepatitis A, hepatitis B if not immune, typhoid; atovaquone-proguanil chemoprophylaxis for malaria areas; repellent, permethrin-treated clothing, screened or air-conditioned quarters and bed nets against mosquitoes, fleas, lice and mites; food and water precautions with standby azithromycin; primaquine terminal prophylaxis after leaving the malaria areas, and a malaria test for any fever after return. Guideline: CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026); French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Dengue (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Rickettsial Diseases (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Travelers' Diarrhea (2026); The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006) **S**

## Follow-up

- 1705-02-17: New patient visit for recurrent fevers with chills after naval service in malaria-endemic areas, and an expected tropical deployment: history, examination, malaria testing, quantitative G6PD, and an infectious diseases (travel medicine) referral **S**
- 1705-03-03: Two-week follow-up and infectious diseases consultation: PCR result and radical cure **S**
- 1705-03-31: Six-week review after chloroquine and primaquine: blood count, adverse effects, relapse surveillance **S**
- 1705-04-21: Periodic adult preventive visit **S**
- 1705-07-28: Pre-travel visit: yellow fever, hepatitis A, hepatitis B and typhoid vaccines, and the travel plan **S**
- 1705-10-13: Pre-departure review: no relapse, malaria chemoprophylaxis, vector, food and water precautions, standby treatment, and the plan on return **S**

This teaching document does not replace care from a qualified clinician.
